Prostate cancer imaging has moved well beyond the standard ultrasound of past decades. A scientific review published in May 2026 by researchers Ahmed Rabie, Maurizio Buscarini, and Osama Zaytoun in the journal Frontiers in Urology describes three next-generation techniques—multiparametric MRI, micro-ultrasound, and PSMA PET—each suited to a different point in the diagnostic journey. mpMRI leads in initial detection and biopsy guidance, micro-ultrasound offers real-time precision at lower cost, and PSMA PET excels at finding cancer that has spread or returned. Understanding their distinct strengths and limitations can help patients ask sharper questions during consultations.
Multiparametric MRI (mpMRI): A Detailed Look
Multiparametric MRI combines several imaging sequences—T2-weighted anatomical imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging—to read different characteristics of prostate tissue at once. According to the review, this layered approach gives mpMRI high sensitivity for clinically significant prostate cancer, meaning tumors that genuinely warrant treatment rather than harmless findings.
Two practical features strengthen its clinical standing. Interpretation follows a standardized reporting system called PI-RADS, which helps reduce inconsistency between readers, and the scan involves no ionizing radiation. It also enables targeted biopsy: suspicious areas seen on the scan can be sampled directly rather than relying on random sampling alone.
The limitations are real, however. The review lists high cost, limited availability in some regions, and interobserver variability in interpretation—different radiologists can read the same scan differently. mpMRI may also miss small lesions or tumors located in the anterior prostate or transition zone, regions where the disease can hide.
